PLK4抑制剂CFI-400945的临床前特征及在复发/难治性急性髓系白血病和高危骨髓增生异常肿瘤患者中的临床试验
CFI-400945是一种选择性口服PLK4抑制剂。在针对复发/难治性AML和MDS极高危患者的1期研究中,13例患者接受64至128 mg/天持续给药,9例可评估AML患者中3例达完全缓解,4例TP53突变AML患者中2例达完全缓解,剂量限制性毒性为肠炎/结肠炎。
要点
- CFI-400945为口服选择性PLK4抑制剂,临床前研究显示对TP53突变细胞有活性。
- 9例可评估AML患者中3例达完全缓解,4例TP53突变AML患者中2例达完全缓解。
- 剂量限制性毒性为肠炎/结肠炎,1例完全缓解患者后续接受异基因干细胞移植。
核心结论
- CFI-400945在复发/难治性AML和MDS极高危患者中显示出临床活性,3/9例可评估AML患者达完全缓解。
研究设计与样本
- 1期剂量递增研究(NCT03187288),纳入复发/难治性AML和骨髓增生异常综合征极高危患者,13例接受CFI-400945持续给药,剂量从64 mg/天递增至128 mg/天。
主要发现
- 9例可评估AML患者中3例达完全缓解。
- 4例TP53突变且复杂单体核型AML患者中2例(50%)达完全缓解,其中1例后续接受异基因干细胞移植。
- 另1例TP53突变AML患者骨髓原始细胞减少>50%,中性粒细胞和血小板计数改善。
- 缓解在1个疗程后观察到。
- 剂量限制性毒性为肠炎/结肠炎。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CFI-400945 is a selective oral polo-like kinase 4 (PLK4) inhibitor that regulates centriole duplication. PLK4 is aberrantly expressed in patients with acute myeloid leukemia (AML). Preclinical studies indicate that CFI-400945 has potent in vivo efficacy in hematological malignancies and xenograft models, with activity in cells harboring TP53 mutations. In this phase 1 study in very high-risk patients with relapsed/refractory AML and myelodysplastic syndrome (MDS) (NCT03187288), 13 patients were treated with CFI-400945 continuously in dose escalation from 64 mg/day to 128 mg/day. Three of the 9 efficacy evaluable AML patients achieved complete remission (CR). Two of 4 AML patients (50%) with TP53 mutations and complex monosomal karyotype achieved a CR with 1 patient proceeding to allogenic stem cell transplant. A third patient with TP53 mutated AML had a significant reduction in marrow blasts by > 50% with an improvement in neutrophil and platelet counts. Responses were observed after 1 cycle of therapy. Dose-limiting toxicity was enteritis/colitis. A monotherapy and combination therapy study with a newer crystal form of CFI-400945 in patients with AML, MDS and chronic myelomonocytic leukemia (CMML) is ongoing (NCT04730258).
引用
- Murphy T, Mason JM, Leber B, et al. Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia. 2023. PMID: 38114624. doi:10.1038/s41375-023-02110-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。